No, Adults Cannot Use Daytrana
Daytrana (methylphenidate transdermal system) is FDA-approved only for pediatric patients ages 6 to 17 years and is explicitly NOT indicated for adult use. 1
FDA-Approved Indication
The FDA drug label is unequivocal: Daytrana is indicated exclusively for "the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age" 1. There is no adult indication, and prescribing it off-label for adults would be outside the approved scope of use.
Why This Matters Clinically
While methylphenidate as a drug class is well-established for adult ADHD treatment 2, the transdermal delivery system (Daytrana) has specific pharmacokinetic properties that have only been studied and approved in children and adolescents. The FDA approval process requires age-specific safety and efficacy data, which Daytrana lacks for adults.
Evidence on Methylphenidate in Adults (But Not Daytrana Specifically)
- Oral methylphenidate is effective in adults with ADHD, with controlled studies showing 23-78% response rates at doses of 5-20 mg three times daily 2
- Guidelines support stimulant use in "carefully evaluated adults with ADHD" 2
- Two small research studies examined Daytrana specifically in adults 3, 4, showing potential efficacy, but these were limited open-label or crossover trials that cannot override FDA labeling restrictions
Practical Prescribing Reality
For adult ADHD, prescribe FDA-approved adult formulations of methylphenidate instead:
- Immediate-release methylphenidate tablets (5-20 mg tid) 2
- Extended-release oral formulations approved for adults (Concerta, others)
- Dexmethylphenidate (5 mg tid to 20 mg bid) 2
Key Clinical Caveats
- Substance abuse history: Exercise extreme caution when prescribing any stimulant to adults with comorbid substance use disorders 2
- Comprehensive evaluation required: Adults need thorough psychiatric assessment, collateral history, screening for comorbidities (depression, anxiety, bipolar disorder, personality disorders), and documentation of childhood-onset symptoms 2
- Dermatologic concerns: Even in the limited adult research with Daytrana, dermatologic adverse events were notably problematic 3
Prescribing Pattern Data
Real-world data confirms the pediatric focus: 88% of Daytrana users were children and adolescents, compared to only 57% for the broader ADHD medication market 5. This reflects both the FDA indication and clinical practice patterns.
Bottom line: Use FDA-approved oral methylphenidate formulations for adults with ADHD. Daytrana should remain restricted to its approved pediatric population (ages 6-17 years).